NL-OMON47719招募中4 期
A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis - Golimumab-MK8259-GO-BACK
Merck Sharp & Dohme (MSD)0 个研究点目标入组 13 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1.Be male or female and must be >= 18 to <= 45 years of age;2.Be able to provide written informed consent for the trial and may also provide consent for Future Biomedical Research. However, the subject may participate in the trial without participating in Future Biomedical Research;3. Meet one of the following categories:;a) The subject is not of reproductive potential, defined as a male who has azoospermia OR as a female who is either: (1)Postmenopausal (2) has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion; OR (3) has a congenital or acquired condition that prevents childbearing.;b) The subject is a female or a male who is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication by complying with one of the following: (1) practice abstinence* from heterosexual activity OR (2) use (or have their partner use) acceptable contraception during heterosexual activity.;Acceptable methods of contraception are defined in the protocol.;4.Have chronic back pain of >=3 months duration by history;5.Have a physician*s diagnosis of active nr-axSpA with disease duration <=5 years;6.Meet either criterion *a* or *b* as adopted from ASAS classification criteria: a)Active inflammation on MRI highly suggestive of sacroiliitis associated with spondyloarthropathy and 1 or more of the spondyloarthritis;characteristics as described in the protocol. b)HLA-B27+ gene and 2 or more of the spondyloarthritis characteristics as described in the protocol;7.Have elevated CRP at the Screening visit or evidence of active inflammation in the SI joints on MRI;8.Have ASDAS >=2.1 at the Screening visit;9.Show high disease activity at Screening and Baseline of both a Total Back Pain score of >=4 and a BASDAI score of >=4 (each on a NRS of 0 to 10);10.Have an acceptable history of use of NSAIDs: either an inadequate response, as assessed by the investigator, with maximal recommended daily doses of at least 2 NSAIDs; or must be unable to receive maximal NSAID therapy because of intolerance, toxicity, or contraindications to NSAIDs. (Note: It is possible that a subject had a good response initially to NSAIDs but subsequently had inadequate response or developed intolerance to NSAIDs therapy);11.Have acceptable current use of NSAIDs at Screening: a)If currently using an NSAID, must be on a stable daily dose for at least 14 days prior to Screening b)If not currently using an NSAID, short-term use is allowed (up to 1 week) during Period 1 and is allowed as needed during Period 2;12.Have no history of untreated latent or active tuberculosis;13.Be judged to be medically stable, other than nr-axSpA, based on medical history, physical examination, and routine laboratory tests;14.Undergo screening for hepatitis B virus (HBV), which at a minimum includes testing for HBV surface antigen (HBsAg), HBV surface antibody (anti-HBs), and HBV core antibody (anti-HBc total), and demonstrate to be eligible based on the results as described in the protocol
排除标准
- •1.Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4 on conventional x-rays (to exclude subjects who meet modified New York criteria for AS);2.If female, is nursing, pregnant, or intending to become pregnant within 6 months after receiving the last administration of trial medication;3. Intends to donate eggs (female subjects) or sperm (male subjects) while receiving trial medication or within 6 months after the last dose of trial medication.;4.Has any clinically significant condition or situation, other than those listed as exclusion criteria that, in the opinion of the investigator, would interfere with the trial evaluations or participation in the trial;5.Has ever received any cytotoxic drugs, including but not limited to chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents;6. Has received any treatment as described in the protocol more recently than the indicated offdrug period prior to Screening;7.Has ever received TNF-a targeted therapy or any other biological agents intended to treat immune-mediated diseases, including but not limited to infliximab, etanercept, adalimumab, certolizumab, golimumab, alefacept, efalizumab, rituximab, natalizumab, secukinumab, ixekizumab, ustekinumab, or vedolizumab;8.Has an allergy/sensitivity to golimumab or its excipients;9.Has any systemic inflammatory condition from Screening up to Baseline with signs and symptoms including, but not limited to: a. psoriatic arthritis, b. active Lyme disease, c. systemic lupus erythematosus, d. infectious arthritis, e. vasculitis, f. parvovirus infection, g. rheumatoid arthritis, h. active uveitis, i. active IBD;10.Has a history of latent or active granulomatous infection, including histoplasmosis, or coccidioidomycosis, prior to Screening;11.Had a nontuberculous mycobacterial infection or opportunistic infection (e.g., cytomegalovirus, Pneumocystis jirovecii [carinii], aspergillus) within 6 months prior to Screening;12.Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced;13.Had a serious infection (including but not limited to, hepatitis, pneumonia, sepsis, or pyelonephritis), or has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline. Less serious infections (eg, acute upper respiratory tract infection, simple urinary tract infection) need not be considered exclusionary at the discretion of the investigator;14.Had a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis), sinusitis, recurrent urinary tract infection (e.g., recurrent pyelonephritis, chronic nonremitting cystitis), an open, draining, or infected skin wound, or an ulcer;15.Is known to be infected with human immunodeficiency virus (HIV) or seropositive for hepatitis C virus (HCV);16.Has a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or malignancy;17.Has a history of lymphoproliferative disease, including lymphoma, or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location and/or clinically significant splenomegaly, or monoclonal gammopathy of undetermined significance;18.Has had a malignancy within 5 years before screeni
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644